Physician profile
Ali Haider
NPI 1538435060
$1,146.55
in general payments reported to CMS, 2019-2025
15 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.25 · 2021: $75.29 · 2022: $150 · 2023: $125 · 2024: $319 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.64 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.56 | 2021-2025 | |
| Janssen Biotech, INC. | $293.72 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $163.62 | 2021-2025 | Entyvio |
| Endogastric Solutions, INC | $72.13 | 2022 | |
| Lilly USA, LLC | $65.01 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $51.92 | 2025 | Dupixent |
| Exact Sciences Corporation | $29.15 | 2024 | Cologuard Collection Kit |
| Medtronic, INC. | $28.99 | 2022 | |
| Ardelyx, INC. | $28.85 | 2025 | Ibsrela |
| Pacira Pharmaceuticals Incorporated | $24.37 | 2019 | |
| Gilead Sciences, INC. | $24.02 | 2022 | |
| Novo Nordisk INC | $20.09 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $18.78 | 2023 | Inpefa |
| Echosens North America, INC. | $15.05 | 2024 | Fibroscan |
| Intercept Pharmaceuticals, INC. | $13.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.